The Categories Nobody Is Watching
Of the 1,186 active drug shortages the FDA is tracking as of this week, the loudest numbers belong to anesthesia (176), psychiatry (155) and pediatric medicine (142). Those three categories get the headlines because they touch operating rooms, stimulant prescriptions and children's dosing, all politically sensitive. But four other categories, gastroenterology (87), the FDA's catch-all Other bucket (75), endocrinology/metabolism (67) and oncology (54), together account for 283 shortages, nearly a quarter of the entire list. These are quieter crises, and that is precisely why buyers and clinicians tend to miss the inflection points until a formulary substitution is already forced.
Parenteral Nutrition Sits at the Intersection
The clearest example of how these mid-tier categories overlap is Baxter Healthcare's Amino Acid Injection, which appears nine separate times in this week's shortage data under different strengths and package configurations. Amino acid injections are the backbone of parenteral nutrition, used for patients who cannot absorb nutrients through the gut, a population that spans gastroenterology (short bowel syndrome, severe Crohn's disease, post-surgical ileus) and endocrinology/metabolism (inborn errors of metabolism, severe malnutrition in endocrine disease). A single manufacturer's product line generating nine distinct shortage entries is a structural signal, not a coincidence. It means Baxter is effectively carrying concentration risk across two of the FDA's largest non-headline categories simultaneously, and any disruption at a single fill-finish line ripples into both GI and metabolic-disease patient populations at once.
Gastroenterology's 87 Shortages
Gastroenterology's shortage count sits above oncology, above neurology, and not far behind endocrinology, yet it rarely gets separate coverage because GI drugs skew toward older, cheap generics: injectable antiemetics, electrolyte replacement products, and nutrition support formulations like the Baxter amino acid line. These are exactly the products economics has taught generic manufacturers to deprioritize. Margins are thin, contracts are won on lowest bid through group purchasing organizations, and any single-site quality problem or raw-material delay removes capacity that competitors are not incentivized to backfill quickly. The result is a category that quietly holds 87 shortages without ever producing the kind of dramatic news cycle that sterile injectable anesthesia drugs generate.
Endocrinology and Metabolism: 67 and Rising in Relevance
Endocrinology/metabolism's 67 active shortages matter disproportionately because this category includes chronic-disease therapies where even short interruptions force dose changes or therapeutic substitutions that patients and pharmacists have to manage in real time, unlike a one-time surgical anesthetic. The category's overlap with the nutrition-support drugs also listed under gastroenterology, again visible in the Baxter amino acid injection entries, means metabolic patients dependent on total parenteral nutrition are exposed twice: once through GI-coded shortages and once through endocrinology-coded ones. Buyers managing formularies for metabolic disease centers or home infusion pharmacies should treat these two categories as a single combined risk pool rather than tracking them separately.
Oncology's Smaller but Sharper List
Oncology carries 54 active shortages, the smallest count among the eight categories in today's data, but the clinical stakes per shortage are higher because substitution options in cancer regimens are often protocol-driven and less flexible than in other therapeutic areas. A shortage count under 60 sounds manageable next to anesthesia's 176, but oncology pharmacists know that even a handful of missing generic injectables can force treatment delays or regimen modifications for patients on curative-intent chemotherapy. The category's relatively lower count should not be read as lower urgency.
What Buyers and Clinicians Should Watch
The first thing to track is NDC-level repetition within a single manufacturer's product line, the way Baxter's Amino Acid Injection shows up nine times and Alvogen's amphetamine combination tablet shows up three times in the same dataset. Multiple listings under one company for one drug family indicate that a shortage is systemic to that manufacturer's supply chain rather than an isolated lot or strength issue, and buyers should treat single-source dependency on that manufacturer as elevated risk regardless of which therapeutic category the FDA files it under.
Second, watch the categories that sit below the headline threshold. Gastroenterology's 87, Other's 75 and endocrinology/metabolism's 67 shortages are large enough in aggregate to strain hospital pharmacy budgets and home infusion networks, even though no single drug in those categories tends to generate national media coverage. Procurement teams should build alerts around these categories specifically because the market is not doing that work for them.
Third, cross-reference nutrition support products across categories. Parenteral nutrition components like amino acid injections do not respect the FDA's category labels, and a shortage coded under gastroenterology can just as easily hit an endocrinology-coded patient population. Hospital P&T committees managing TPN protocols should be pulling shortage data for both categories jointly, not separately.
The Forward View
Anesthesia, psychiatry and pediatric shortages will keep dominating shortage coverage because they are the largest single categories and the most visible to the public. But the 283 shortages sitting in gastroenterology, Other, endocrinology/metabolism and oncology represent a slower-moving but structurally similar problem, thin-margin generics, concentrated manufacturing, and demand that does not disappear when supply does. As FDA shortage totals hover above 1,180 heading into the fourth quarter of 2026, the categories that get fixed first will likely be the ones generating political pressure, not necessarily the ones causing the most clinical disruption. Buyers who build monitoring systems around manufacturer-level concentration, rather than category labels alone, will see the next wave of shortages before the FDA's own list catches up.